Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

[1]  M. Loda,et al.  Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer , 2000, Genes, chromosomes & cancer.

[2]  M. Lerner,et al.  Expression of the cyclin‐dependent kinase inhibitor p21WAF1/CIP1 and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus , 1999, Cancer.

[3]  E. Bergstralh,et al.  CLINICAL SIGNIFICANCE OF ALTERATIONS OF CHROMOSOME 8 IN PATHOLOGICAL STAGE T3 N0 M0 PROSTATE CARCINOMA , 1999 .

[4]  C. Cordon-Cardo,et al.  Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. , 1999, Journal of the National Cancer Institute.

[5]  D. Bostwick,et al.  Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen , 1998, Cancer.

[6]  S. Mayor,et al.  GPI-anchored proteins are organized in submicron domains at the cell surface , 1998, Nature.

[7]  T. Kurzchalia,et al.  Microdomains of GPI-anchored proteins in living cells revealed by crosslinking , 1998, Nature.

[8]  M. Rubin,et al.  Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications. , 1998, The American journal of surgical pathology.

[9]  R. Xavier,et al.  Membrane compartmentation is required for efficient T cell activation. , 1998, Immunity.

[10]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Loda,et al.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Hoessli,et al.  GPI-anchors and cell membranes: a special relationship. , 1998, Trends in cell biology.

[13]  J. Epstein,et al.  Immunoreactivity for prostate‐specific antigen and prostatic acid phosphatase in adenocarcinoma of the prostate: Relation to progression following radical prostatectomy , 1998, The Prostate.

[14]  G. Arienti,et al.  Prostasome to sperm transfer of CD13/aminopeptidase N (EC 3.4.11.2). , 1997, Biochimica et biophysica acta.

[15]  W. Fair,et al.  Prostate‐specific membrane antigen , 1997, The Prostate.

[16]  M. Cheever,et al.  HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. , 1997, Advances in cancer research.

[17]  M. Antica,et al.  Stem cell antigen 2 expression in adult and developing mice. , 1997, Immunology letters.

[18]  M. Loda,et al.  Molecular events in the early phases of prostate carcinogenesis. , 1996, European urology.

[19]  A W Partin,et al.  OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. , 1995, Urology.

[20]  R. Bookstein,et al.  Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer , 1994, Genes, chromosomes & cancer.

[21]  B. Classon,et al.  Mouse stem cell antigen Sca-2 is a member of the Ly-6 family of cell surface proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. G. Anderson,et al.  Caveolae: where incoming and outgoing messengers meet. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  W. Knapp,et al.  GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. , 1991, Science.

[24]  T. Stamey,et al.  Cribriform adenocarcinoma of the prostate , 1986, Cancer.